Osteoarthritis: New trial drug may have powerful anti-inflammatory effect

Author(s): Riley Kleemeier

Researchers from the University of Liverpool, in collaboration with the pharmaceutical company AKL Research & Development, have found a new drug (APPA) that has the potential to treat osteoarthritis, rheumatoid arthritis, and other conditions resulting from inflammation.

APPA has shown that it may help keep the immune system functioning properly and reduce “bad” inflammation, while simultaneously ensuring that its protective functions still work.

The trial data also may have the potential to impact treatment for COVID-19 in terms of the inflammation associated with the condition.

Please read more about the trial drug here.
Source: https://link.springer.com/article/10.1007/s10787-020-00715-5


Please enter your comment!
Please enter your name here